GI
JANX icon

GAMMA Investing’s Janux Therapeutics JANX Stock Holding History

GAMMA Investing’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$28.4K Buy
1,642
+661
+67% +$11.1K ﹤0.01% 2730
2026
Q2 		$15.1K Buy
981
+253
+35% +$3.67K ﹤0.01% 2993
2026
Q1 		$10.1K Buy
728
+712
+4,450% +$9.76K ﹤0.01% 3064
2025
Q4 		$221 Buy
16
+8
+100% +$188 ﹤0.01% 3992
2025
Q3 		$196 Sell
8
-38
-83% -$925 ﹤0.01% 3801
2025
Q2 		$1.06K Sell
46
-16
-26% -$422 ﹤0.01% 3526
2025
Q1 		$1.67K Sell
62
-38
-38% -$1.43K ﹤0.01% 3455
2024
Q4 		$5.35K Buy
100
+68
+213% +$3.6K ﹤0.01% 2894
2024
Q3 		$1.45K Buy
32
+7
+28% +$305 ﹤0.01% 3157
2024
Q2 		$1.05K Buy
25
+7
+39% +$329 ﹤0.01% 3047
2024
Q1 		$678 Buy
+18
New +$392 ﹤0.01% 3034

Other funds holding JANX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

GAMMA Investing's JANX Position: Q3 2026 in Review

GAMMA Investing increased its Janux Therapeutics (JANX) stake by 67% in Q3 2026, buying an estimated $11.1K and bringing the position to 1,642 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

GAMMA Investing first reported a position in JANX in Q1 2024 and has held it in 11 quarters since. 5 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • GAMMA Investing held 1,642 shares of Janux Therapeutics worth $28.4K as of Q3 2026.
  • GAMMA Investing bought 661 Janux Therapeutics shares in Q3 2026, an estimated $11.1K.
  • Janux Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2730 holding.
  • GAMMA Investing first reported a position in Janux Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 5 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.